SCHEMBL3462909

SCHEMBL3462909

C/C=C/C(=O)n1nnc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.61
NPSR1 Q6W5P4 2/20 0.61
GAA P10253 10/20 0.55
MGAM O43451 9/20 0.55
AMY1A P0DUB6 9/20 0.55
SI P14410 9/20 0.55
MGAM2 Q2M2H8 9/20 0.55
KMT2A Q03164 3/20 0.55
F2 P00734 2/20 0.55
HPGD P15428 1/20 0.55
SLC9A1 P19634 1/20 0.55
DGAT1 O75907 1/20 0.53
KCNMA1 Q12791 1/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HTT P42858 1/20 0.51
F12 P00748 4/20 0.50
MIF P14174 1/20 0.50
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490623 1.00 MAPT (0.61) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL13559645 0.83 MAPT (0.64) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL461244 0.81 MAPT (0.74) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL461243 0.81 MAPT (0.74) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL13518869 0.81 GAA (0.57) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL3689328 0.80 GAA (0.58) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL535054 0.78 GAA (0.64) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL4250719 0.77 GAA (0.68) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL706083 0.77 MGAM (0.68) MAPTNPSR1GAAMGAMAMY1A
SCHEMBL463197 0.77 MAPT (0.70) MAPTNPSR1GAAMGAMAMY1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102379-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS POINT LOMA NAZARENE UNIVERSITY 2023-03-30 US claimed
WO-2021150951-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-29 WO claimed
EP-2014797-A2 Coating composition for interconnection part of electrode and plasma display panel including the same Samsung SDI Co., Ltd. (KR) 2009-01-14 EP claimed
US-20080303439-A1 Coating composition for interconnection part of electrode and plasma display panel including the same SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) 2008-12-11 US claimed
US-20230102379-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS POINT LOMA NAZARENE UNIVERSITY 2023-03-30 US disclosed
WO-2021150951-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-29 WO disclosed
WO-2021150951-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-29 WO disclosed
US-8330039-B2 Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound E I DU PONT DE NEMOURS AND COMPANY (US) 2012-12-11 US disclosed
US-20100180947-A1 SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-07-22 US disclosed
US-20080303439-A1 Coating composition for interconnection part of electrode and plasma display panel including the same SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) 2008-12-11 US disclosed
US-7351849-B2 Process for producing optically active β-amino acid derivatives TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-04-01 US disclosed
US-7351849-B2 Process for producing optically active β-amino acid derivatives TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230102379-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS LSS, REL, RPN1 MAPT 4107/4885NPSR1 3483/4885GAA 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.